Different Effects on Oestrogen Binding Sites and Anti-Oestrogenic Action of Danazol and Progesterone

In: Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · 1991 · vol. 28(3) , pp. 250–252 · doi:10.1177/000456329102800309 · PMID:1872570 · W2334135111
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-09

Progesterone and danazol inhibited estrogen-stimulated uterine weight increases by decreasing estrogen binding sites, with danazol potentially acting via a different pathway than progesterone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Rabbit uterus contains type I and II oestrogen binding sites in the cytosol, and nuclear fractions. Oestrogen-stimulated increase in uterine weight was inhibited by concurrent treatment with progesterone or danazol. Oestrogen-induced type I binding sites were decreased by progesterone and to a lesser extent by danazol, while oestrogen-induced type II sites were decreased almost equally in the two groups. Neither progesterone nor danazol alone caused any detectable changes in uterine weight. These findings may suggest that the anti-oestrogenic effect on uterine weight is more correlated with the change in type II binding sites of oestrogen than that in type I sites. Thus, danazol may exert anti-oestrogenic actions through a pathway independent from that of progesterone.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (3)

References (7)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-10T10:29:31.028256+00:00
License: CC0 · commercial use OK